See the DrugPatentWatch profile for Aromasin
Aromasin (exemestane) is an aromatase inhibitor used for hormone-receptor–positive breast cancer in postmenopausal people. It lowers estrogen production by blocking the aromatase enzyme, helping slow or stop estrogen-driven tumor growth.
What is Aromasin used for?
Aromasin is prescribed for postmenopausal patients with estrogen-receptor–positive breast cancer, including:
- Early breast cancer treatment in certain post-surgery sequences (commonly as an option after tamoxifen)
- Advanced or metastatic breast cancer when the disease has progressed after earlier endocrine therapy
How does Aromasin work?
Aromasin (exemestane) is a steroidal aromatase inhibitor. By inhibiting aromatase, it reduces conversion of androgens into estrogen in peripheral tissues, which lowers circulating estrogen levels and deprives hormone-sensitive tumors of a growth signal.
How is Aromasin typically taken?
Dosing is generally once daily by mouth in the breast-cancer setting (exact dose and schedule depend on the individual regimen your clinician prescribes). Patients are typically counseled to follow the specific prescription instructions and dosing schedule.
What side effects are patients asking about?
Common patient-reported or clinically expected effects with aromatase inhibitors can include:
- Joint and muscle pain (arthralgia/myalgia)
- Hot flashes
- Fatigue
- Nausea or gastrointestinal discomfort
- Changes in bone density over time, which can increase fracture risk in some patients
If you have a history of osteoporosis, fractures, or are taking bone-active treatments, clinicians often monitor bone health during therapy.
Does Aromasin cause bone loss? What monitoring is done?
Yes. By reducing estrogen, aromatase inhibitors can contribute to decreased bone mineral density. In routine practice, clinicians may order baseline and follow-up bone density testing (DEXA scans) and may recommend calcium/vitamin D and/or bone-protecting therapy depending on risk.
What drug or brand alternatives are there?
Aromasin is one aromatase inhibitor option. Other commonly used aromatase inhibitors include:
- Letrozole
- Anastrozole
- (In some regions/contexts) other endocrine therapy options such as fulvestrant or tamoxifen may be used based on disease stage and prior treatment.
Is Aromasin still under patent, and who makes it?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs, including Aromasin. You can check current status here: DrugPatentWatch.com – Aromasin.
How long is treatment usually continued?
Treatment duration depends on the cancer setting (early vs metastatic), prior therapies, response, and tolerability. Early-stage endocrine therapy is often continued for years, while advanced disease treatment continues while it remains effective and manageable side-effect wise.
When should patients contact a clinician urgently?
Patients should seek prompt medical advice for serious or unusual symptoms such as signs of blood clots, severe shortness of breath, chest pain, or symptoms of significant allergic reactions. For ongoing issues like worsening joint pain or new back pain, clinicians can reassess dose strategy, switching therapies, and bone-protection plans.
If you tell me what you need—side effects, dosing, interactions, insurance/pricing, or whether a generic exists in your country—I can tailor the answer to that goal.
Sources:
1. https://www.drugpatentwatch.com/